HSIC · Q4 2025 Earnings
CautiousHenry Schein
Reported February 24, 2026
30-second summary
Henry Schein closed FY2025 at $4.97 non-GAAP EPS — a penny above the high end of the raised guide — on Q4 revenue of $3.44B (+7.7% YoY), then set FY2026 EPS guidance of $5.23–$5.37 (5–8% growth) while leaving sales growth guidance unchanged at 3–5% and EBITDA growth at mid-single digits. The setup matters: management explicitly weighted 2026 earnings growth to the second half, assumes "stable" rather than improving end markets, and is anchoring the bull case on the $200M value creation program (now $125M by end of 2026). The Q3 "back in its stride" momentum is preserved in the FY2025 print but not extended into the FY2026 framing.
Headline numbers
EPS
Q4 FY2025
$1.34
Revenue
Q4 FY2025
$3.44B
+7.7% YoY
Gross margin
Q4 FY2025
30.9%
Operating margin
Q4 FY2025
4.7%
Key financials
Q4 FY2025| Metric | Q4 FY2025 | YoY | Q3 FY2025 | QoQ |
|---|---|---|---|---|
| Revenue | $3.44B | +7.7% | $3.34B | +2.9% |
| EPS | $1.34 | — | $1.38 | -2.9% |
| Gross margin | 30.9% | — | 30.7% | +20bps |
| Operating margin | 4.7% | — | 4.9% | -20bps |
Guidance
Henry Schein beat FY2025 EPS guidance while setting FY2026 EPS growth guidance of 5-8% with stable sales growth of 3-5%, indicating continued but moderating momentum.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
Actuals vs prior guidance
| Metric | Period | Prior guide | Actual | Δ | Result |
|---|---|---|---|---|---|
| Non-GAAP Diluted EPS | FY2025 | $4.88 to $4.96 | $4.97 | +$0.01 above guide | Beat |
| Total Sales Growth | FY2025 | 3% to 4% | 4% | +0% above guide | Beat |
New guidance
| Metric | Period | Guide | YoY |
|---|---|---|---|
| Non-GAAP Diluted EPS | FY2026 | $5.23 to $5.37 | +5-8% YoY |
| Total Sales Growth | FY2026 | 3% to 5% | — |
| Adjusted EBITDA Growth | FY2026 | mid-single digits | — |
Segment KPIs
Q4 FY2025| Segment | Q4 FY2025 | YoY |
|---|---|---|
| Global Distribution and Value-Added Services | $2.891B | +7.0% |
| Global Specialty Products | $0.422B | +14.6% |
| Global Technology | $0.173B | +8.4% |
| Global Dental | $1.818B | +8.2% |
| Global Medical | $1.073B | +4.9% |
| Global Merchandise Sales Growth | 6.4% | — |
| Global Equipment Sales Growth | 12.2% | — |
| Global Value-Added Services Growth | 9.6% | — |
Other KPIs
Q4 FY2025| Segment | Q4 FY2025 |
|---|---|
| Internal Sales Growth (Constant Currency) | 4.9% |
| Acquisition-Related Sales Growth | 0.9% |
| Adjusted EBITDA | $291 million |
| Share Repurchases (Q4) | $200 million (2.8M shares) |
| Share Repurchases (Full Year) | $850 million (12.1M shares) |
Management tone
Cyber-recovery reset → strategic outsourcing and CEO transition → momentum regained with $200M target → transformation under new CEO with hedged near-term
The "back in its stride" rhetoric of Q3 has softened into "managing through transformation." Three months ago the anchor quote was "the distribution part of Henry Schein has gained momentum. It's back in its stride. We're winning." This quarter, with new CEO Fred Lowry's voice in the print, the framing is "the fourth quarter results demonstrate that I'm joining a company that is successfully managing through transformation, which is exactly the kind of experience I've led effectively in prior roles." That is a subtle but meaningful downshift — from a company that has fixed its problem to a company that is actively transforming. The empirical performance (Q4 distribution +7.0%, specialty +14.6%) would support a more confident tone; the choice to frame it as transformation-in-progress is a deliberate expectations reset.
Forward visibility has narrowed to long-term initiatives, not near-term demand. In Q3 management spoke directly about market share gains, competitor reps "knocking on our door," and pricing stability. This quarter the forward language pivots to "support our long-term financial goals," "long-term value creation initiatives," and assumes only "stable" end markets. The hedge "patient traffic remains stable and probably leaning positively" is materially weaker than Q3's outright confidence. Combined with explicit H2-weighting of 2026 earnings growth, the signal is that management has less near-term visibility heading into 2026 than they did heading into Q4 2025.
The $200M value creation program is now quantified by year and concentrated in 2026. Q3 framed $200M as "over the next few years" with no annual breakdown. This quarter Ron explicitly committed to "over $125 million by the end of 2026" with the rest extending beyond. That is meaningful disclosure — but the Q&A revealed two important caveats: implementation costs are H1-weighted (creating an earnings headwind in the first half), and "how much flows through to 2027 remains to be determined." Management would not extend a clean run-rate through 2027, which is the most evasive moment in the Q&A and matters because the FY2026 EPS guide of 5–8% growth relies heavily on this program.
AI moves from concept to product with named partners. Q3 mentioned digital initiatives generically. This quarter delivered specifics: an AWS generative-AI partnership integrated into Dentrix Ascend, ImageVerify launched at Chicago Midwinter as an AI-powered quality assessment tool, voice documentation tools in flight, and 11,000+ Dentrix Ascend subscribers cited. This is the most concrete competitive-positioning shift in the print and supports the long-term margin-mix thesis even if it does not move 2026 numbers.
The profit-mix shift is now an explicit target with a number. Stanley quantified "2025 non-GAAP operating income from high growth, high margin businesses is approaching 50% of our total operating income" and said the company is "on track to exceed our goal of over 50% by the end of our strategic planning cycle in 2027." This is the cleanest statement to date of where the company is going strategically and corroborates why distribution-margin pressure is being managed rather than panicked over — the business is being redirected toward Specialty and Technology, where Q4 growth was 14.6% and 8.4% respectively vs 7.0% in Distribution.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Jeff Johnson · Baird
On the $125 million operating income improvement plan run rate targeting 2026, should this be gated sequentially throughout the year, and what portion could flow through to bottom line in 2027?
Ron indicated the initiatives are in early stages with benefits more heavily weighted to the back half of 2026. The initiatives are not linear due to upfront investments in H1. How much flows through to 2027 remains to be determined based on initiative progress and other business needs.
Alan Lewis · Bank of America
Specialty value implants grew double digits while premium implants grew mid-single digits. Can you discuss pricing evolution on both sides and how to think about price growth as a 2026 lever?
Ron stated there is nothing unusual from a pricing perspective and pricing appears stable. Stanley clarified that the growth driver is portfolio mix shift toward higher-growth value brands like Camelot in Germany, which maintains stable pricing while gaining market share. No unusual price increases or pressure on premium brands.
Jason Bednar · Piper Sandler
Market appears to have stepped forward in Q4. What is the durability of that performance? Can you speak to patient traffic, consumer spending, and dentist equipment spending? Is there anything unique in Q4 that wouldn't persist into 2026?
Stanley indicated U.S. market is stable and trending positively based on InShine claims data. Dentists are investing in new technology (scanners, AI, practice management systems). Good market sentiment was evident at trade shows. Much of the improvement reflects Henry Schein's recovery post-cyber incident (Q2 2024) and re-engagement of sales force. International markets are mixed but positive in Brazil and Germany. No unique Q4 items; momentum driven by market stability and internal execution.
John Stancil · JP Morgan
On the $125 million run rate, are implementation costs in the first half a headwind? Is it still a net benefit for the full year despite H1 costs?
Ron confirmed that full-year 2026 will show a net benefit from initiatives despite some lumpiness in quarterly results. Benefit will be weighted more heavily to H2. Management expressed confidence they would be disappointed if there wasn't a net benefit over the course of the full year.
Joe Federico · Stifel
How do you view sustainability of specialty implant double-digit growth? Should we expect high single-digit growth going forward? Color on U.S. implant performance?
Ron clarified that specialty should grow 5-8% per previous investor day guidance, but current market growth is below that. Outside U.S. (France, Biotech, Camlog) showing good growth. U.S. implant market growing less than 5%. Fourth quarter launch of SynUS value implant in U.S. expected to improve 2026 growth. Double-digit growth is not sustainable every quarter.
Answers to last quarter's watch list
What to watch into next quarter
H1 2026 EPS YoY direction — Management explicitly weighted FY2026 earnings growth to H2 due to value-program implementation costs. Watch whether Q1 EPS is flat or down YoY; a Q1 print below prior-year Q1 would not necessarily breach guidance but would put pressure on the H2 bridge to deliver disproportionate growth, which is the riskier configuration.
Sales growth vs the 3–5% range — FY2026 sales guide low end of 3% is 100bps below FY2025 actuals of 4%. Watch Q1 reported and internal sales growth: a print at or above 4% reinforces the 5% top end of the guide; below 3% would force a guide cut early in the year.
$125M value creation run-rate tracking — Watch for explicit Q1 commentary on how much of the $125M is already in the run rate vs still to be implemented. Anything less than ~$30M booked by Q1 would push the H2 weighting from "back-end loaded" to "Q4-only," which materially raises execution risk.
Specialty Products growth normalization — Q4 grew 14.6%; management explicitly said 5–8% is the durable rate. Watch whether Q1 prints in the 8–12% range (moderating but still healthy) or drops below 8% (mix benefit fading faster than expected).
Distribution gross margin trajectory under new pricing/mix mix — Gross margin recovered 20bps QoQ in Q4 to 30.9%. Watch whether Q1 holds above 30.5% (consistent with the FY2025 31.1% trajectory) or slips back toward 30%, which would reopen the structural-pressure question.
Adjusted EBITDA growth quantification — The qualitative "mid-single digits" framing has now persisted across multiple guides. Watch whether Q1 brings a quantified EBITDA range or the qualitative language hardens — a Q1 raise on EBITDA growth specifically would be a much stronger operating-leverage signal than another EPS-only raise driven by buybacks.
Sources
- Henry Schein Q4 2025 press release, Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/1000228/000100022826000010/exhibit991.htm
- Henry Schein Q4 2025 earnings call (analyst commentary and management responses sourced via extraction; no full transcript available)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.